Delcath Systems' Board Voted To Appoint John Sylvester As New Chairman
(RTTNews) - Interventional oncology company Delcath Systems, Inc. (DCTH) announced Thursday that its Board of Directors has voted to appoint John Sylvester as Delcath's new Chairman. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units.
In addition, Sylvester served as BTG plc's Chief Commercial Officer, leading both their Interventional Oncology and Interventional Vascular businesses, as well as BTG's Chief Development Officer accountable for Strategy, M&A and Market access.
His role at BTG culminated with Boston Scientific's 2019 purchase of BTG for $4.2 billion. Sylvester also built Biocompatibles International plc's Interventional Oncology business, which BTG purchased in 2010.
Switzerland Logs Weaker Growth, Trims 2026 Outlook
U.S. GDP Jumps More Than Previously Estimated In Q2
U.S. Weekly Jobless Claims Edge Down To 229,000
FTSE 100 Down 0.4% In Cautious Trade
CAC Up Slightly; Pernod Ricard Rises On Earnings
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
